BPMC's hCG patent challenged by Kaiser; BPMC seeking royalties of $3-$9 per prenatal test.
This article was originally published in The Gray Sheet
Executive Summary
BPMC'S hCG PATENT CHALLENGED BY KAISER PERMANENTE complaint filed in the U.S. District Court for northern California on Aug. 28. Kaiser maintains that a patent received by Biomedical Patent Management Corp. principal Mark Bogart is not infringed by the "triple marker" test widely used for diagnosis of birth defects in pregnant women, according to the six-page suit. Bogart's patent, #4,874,693, was issued in 1989.